Previous 10 | Next 10 |
The following slide deck was published by Becton, Dickinson and Company in conjunction with their 2021 Q3 earnings call. For further details see: Becton, Dickinson and Company 2021 Q3 - Results - Earnings Call Presentation
Becton, Dickinson (NYSE:BDX) reports financial results for fiscal Q3 ended June 30, 2021. The company recorded quarterly revenues of $4.9B, an increase of 22% over prior year, ahead of abalyst expectation of $4.51B. BD's COVID-19 testing revenues were $300M, including BD Veritor Plus System r...
Becton, Dickinson (NYSE:BDX): Q3 Non-GAAP EPS of $2.74 beats by $0.30; GAAP EPS of $1.72 beats by $0.32. Revenue of $4.89B (+26.7% Y/Y) beats by $380M. FY21 Guidance: Revenues to grow 16.5% to 17.0% (consensus 13.68%) on reported basis, from previous range 12% to 14%; Adjusted EPS: $12.85 and...
Christopher Reidy Announces Intent to Retire from BD Reidy Will Join Board of Directors of Planned Diabetes Care Spinoff PR Newswire FRANKLIN LAKES, N.J. , Aug. 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical t...
BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021 PR Newswire FRANKLIN LAKES, N.J. , Aug. 5, 2021 /PRNewswire/ -- Third fiscal quarter revenues of $4.9 billio...
William von Mueffling's 13F portfolio value increased this quarter from $13.74B to $14.85B. Cantillon increased Facebook, Iqvia Holdings, and Microsoft during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~26% of the 13F po...
BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit PR Newswire FRANKLIN LAKES, N.J. , July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management wil...
The FDA has warned health professionals of an increased risk of a false-positive result with BD SARS-CoV-2 Reagents for the BD Max System test developed by Becton, Dickinson (BDX +0.7%). In one study cited by the manufacturer, there were nearly 3% of false-positive results, the fede...
BD to Begin Remediation for BD Alaris™ System Software PR Newswire FRANKLIN LAKES, N.J. , July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the company w...
S&P 500 Health Care Equipment Index has fared better than the broader index thanks to the performance of medical device companies which have climbed in solidarity with Boston Scientific ([[BSX]] +3.4%) after the medical device maker exceeded expectations with its Q2 2021 financials.C...
News, Short Squeeze, Breakout and More Instantly...
Becton Dickinson and Company Company Name:
BDX Stock Symbol:
NYSE Market:
Becton Dickinson and Company Website:
2024-08-02 11:15:08 ET Raymond James analyst issues OUTPERFORM recommendation for BDX on August 2, 2024 09:49AM ET. The previous analyst recommendation was Outperform. BDX was trading at $239.0875 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-08-02 10:10:00 ET August 2, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Automotive, Biotech and Retail Sectors. The newest automotive stocks are involved in r...
2024-08-02 09:00:11 ET Larry Biegelsen from Wells Fargo issued a price target of $280.00 for BDX on 2024-08-02 08:16:00. The adjusted price target was set to $280.00. At the time of the announcement, BDX was trading at $236.01. The overall price target consensus is at $2...